Collectively, targeting NF-κB, alone or in combination with PI3K/HDAC inhibition, effectively enhances radiosensitivity across multiple cancer types by disrupting DNA repair and promoting G2/M cell cycle arrest, supporting further translational efforts to validate these compounds in clinical settings (77). The gene discussed is NFKB1; the disease is cancer.